Novartis Completes Acquisition of Tourmaline Bio
Novartis has announced the successful completion of its acquisition of Tourmaline Bio, Inc.
As a result of the merger, each outstanding share was canceled and converted into the right to receive consideration per share payable in the tender offer.
The acquisition makes Tourmaline an indirect wholly owned subsidiary of Novartis.
Novartis has announced that it has successfully completed its acquisition of Tourmaline Bio, Inc.
This article was written by Ruchika Sharma, Correspondent for the Business Section at Medical Dialogue.
Author summary: Novartis acquires Tourmaline Bio.
More News
- Flau’jae Johnson Shuts Down Governor’s Call for Charlie Kirk Statue at LSU, Social Media Rides With Her
- Y&R's Peter Bergman on Jack and Victor: 'It's Pure, Virile Hate' (EXCL) - Soap Opera Digest
- O Canada! Summer tourism numbers hit all-time high | RCI
- Romero Elementary stage shines with creativity at pumpkin decorating contest
- Opinion: Nurse licensure compact can strengthen Alaska’s health care workforce | Peninsula Clarion
- Stranger Things 5 Trailer Unleashes All-Out War in Hawkins Ahead of Final Season! | SPIN1038
- Alaska’s Largest Airlift Follows Typhoon Halong
- 31 Days of Frights: Wishmaster > Fandom Spotlite
- Stellantis starts production of the new Jeep Compass at Melfi Plant
- NBA approves $10 billion Lakers sale to Mark Walter